Literature DB >> 26516423

Renal function assessment in atrial fibrillation: Usefulness of chronic kidney disease epidemiology collaboration vs re-expressed 4 variable modification of diet in renal disease.

Rami Riziq-Yousef Abumuaileq1, Emad Abu-Assi1, Andrea López-López1, Sergio Raposeiras-Roubin1, Moisés Rodríguez-Mañero1, Luis Martínez-Sande1, Francisco Javier García-Seara1, Xesus Alberte Fernandez-López1, Jose Ramón González-Juanatey1.   

Abstract

AIM: To compare the performance of the re-expressed Modification of Diet in Renal Disease equation vs the new Chronic Kidney Disease Epidemiology Collaboration equation in patients with non-valvular atrial fibrillation.
METHODS: We studied 911 consecutive patients with non-valvular atrial fibrillation on vitamin-K antagonist. The performance of the re-expressed Modification of Diet in Renal Disease equation vs the new Chronic Kidney Disease Epidemiology Collaboration equation in patients with non-valvular atrial fibrillation with respect to either a composite endpoint of major bleeding, thromboembolic events and all-cause mortality or each individual component of the composite endpoint was assessed using continuous and categorical ≥ 60, 59-30, and < 30 mL/min per 1.73 m(2) estimated glomerular filtration rate.
RESULTS: During 10 ± 3 mo, the composite endpoint occurred in 98 (10.8%) patients: 30 patients developed major bleeding, 18 had thromboembolic events, and 60 died. The new equation provided lower prevalence of renal dysfunction < 60 mL/min per 1.73 m(2) (32.9%), compared with the re-expressed equation (34.1%). Estimated glomerular filtration rate from both equations was independent predictor of composite endpoint (HR = 0.98 and 0.97 for the re-expressed and the new equation, respectively; P < 0.0001) and all-cause mortality (HR = 0.98 for both equations, P < 0.01). Strong association with thromboembolic events was observed only when estimated glomerular filtration rate was < 30 mL/min per 1.73 m(2): HR is 5.1 for the re-expressed equation, and HR = 5.0 for the new equation. No significant association with major bleeding was observed for both equations.
CONCLUSION: The new equation reduced the prevalence of renal dysfunction. Both equations performed similarly in predicting major adverse outcomes.

Entities:  

Keywords:  Anticoagulants; Atrial fibrillation; Follow-up studies; Kidney; Prognosis

Year:  2015        PMID: 26516423      PMCID: PMC4620080          DOI: 10.4330/wjc.v7.i10.685

Source DB:  PubMed          Journal:  World J Cardiol


  28 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.

Authors:  Margaret C Fang; Alan S Go; Yuchiao Chang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Daniel E Singer
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

3.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

4.  Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope.

Authors:  Stefan H Hohnloser; Stuart J Connolly
Journal:  Eur Heart J       Date:  2011-08-28       Impact factor: 29.983

Review 5.  Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program.

Authors:  Gary L Myers; W Greg Miller; Josef Coresh; James Fleming; Neil Greenberg; Tom Greene; Thomas Hostetter; Andrew S Levey; Mauro Panteghini; Michael Welch; John H Eckfeldt
Journal:  Clin Chem       Date:  2005-12-06       Impact factor: 8.327

6.  Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).

Authors:  Elsayed Z Soliman; Ronald J Prineas; Alan S Go; Dawei Xie; James P Lash; Mahboob Rahman; Akinlolu Ojo; Val L Teal; Nancy G Jensvold; Nancy L Robinson; Daniel L Dries; Lydia Bazzano; Emile R Mohler; Jackson T Wright; Harold I Feldman
Journal:  Am Heart J       Date:  2010-06       Impact factor: 4.749

7.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

8.  Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding).

Authors:  Vanessa Roldán; Francisco Marín; Hermógenes Fernández; Sergio Manzano-Fernández; Pilar Gallego; Mariano Valdés; Vicente Vicente; Gregory Y H Lip
Journal:  Am J Cardiol       Date:  2013-01-18       Impact factor: 2.778

9.  Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study.

Authors:  Michiel J Bos; Peter J Koudstaal; Albert Hofman; Monique M B Breteler
Journal:  Stroke       Date:  2007-10-25       Impact factor: 7.914

10.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

View more
  3 in total

1.  Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry.

Authors:  Eitaro Kodani; Hirotsugu Atarashi; Hiroshi Inoue; Ken Okumura; Takeshi Yamashita; Hideki Origasa
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2018-01-01

2.  Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry.

Authors:  Eitaro Kodani; Hiroshi Inoue; Hirotsugu Atarashi; Hirofumi Tomita; Ken Okumura; Takeshi Yamashita; Hideki Origasa
Journal:  Int J Cardiol Heart Vasc       Date:  2020-06-10

3.  Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study.

Authors:  Hirotsugu Atarashi; Shinichiro Uchiyama; Hiroshi Inoue; Takanari Kitazono; Takeshi Yamashita; Wataru Shimizu; Takanori Ikeda; Masahiro Kamouchi; Koichi Kaikita; Koji Fukuda; Hideki Origasa; Hiroaki Shimokawa
Journal:  Heart Vessels       Date:  2021-03-16       Impact factor: 2.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.